800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

view all Clinical Trials

Overview

A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.

Clinical Trial Information

Protocol

IRB#: 32303

Phase

1

Condition(s)

Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Myasthenia Gravis, Muscle Weakness

Investigator

Drs. Terry Heiman-Patterson and Christina Martin Schaff

Coordinator

Kathleen Hatala, RN, BSN, Christine Barr, RN
215-707-7845

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, call 215-707-7845 or email [email protected].

Full Title

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases